FMI
CRVS icon

F/M Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

F/M Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
167,165
+67,136
+67% +$932K 0.13% 113
2026
Q1 		$1.46M Buy
+100,029
New +$1.6M 0.1% 128

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

F/M Investments's CRVS Position: Q2 2026 in Review

F/M Investments increased its Corvus Pharmaceuticals (CRVS) stake by 67% in Q2 2026, buying an estimated $932K and bringing the position to 167,165 shares worth $2.5M. The position accounts for 0.13% of the portfolio, ranked #113.

F/M Investments first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • F/M Investments held 167,165 shares of Corvus Pharmaceuticals worth $2.5M as of Q2 2026.
  • F/M Investments bought 67,136 Corvus Pharmaceuticals shares in Q2 2026, an estimated $932K.
  • Corvus Pharmaceuticals made up 0.13% of F/M Investments's portfolio in Q2 2026, its #113 holding.
  • F/M Investments first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.